EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, ImmunityBio's enterprise value is $6,519.74 Mil.
ImmunityBio's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $0.62 Mil. Therefore, ImmunityBio's EV-to-Revenue for today is 10,481.89.
The historical rank and industry rank for ImmunityBio's EV-to-Revenue or its related term are showing as below:
IBRX'
s EV-to-Revenue Range Over the Past 10 Years
Min: 2087.3 Med: 4643.61 Max: 22801.91
Current: 10481.89
During the past 5 years, the highest EV-to-Revenue of ImmunityBio was 22801.91. The lowest was 2087.30. And the median was 4643.61.
IBRX's EV-to-Revenue is ranked worse than 98.65% of 1035
companies
in the Biotechnology industry
Industry Median: 8.07
vs IBRX: 10481.89
As of today (2024-05-04), ImmunityBio's stock price is $9.15.
ImmunityBio's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00. Therefore, ImmunityBio's PS Ratio for today is 9,150.00.
ImmunityBio EV-to-Revenue Historical Data
The historical data trend for ImmunityBio's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of ImmunityBio's EV-to-Revenue
For the Biotechnology subindustry, ImmunityBio's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ImmunityBio's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ImmunityBio's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where ImmunityBio's EV-to-Revenue falls into.
ImmunityBio's current Enterprise Value is $6,519.74 Mil.
ImmunityBio's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.62 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ImmunityBio's share price for today is $9.15.
ImmunityBio's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ImmunityBio EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of ImmunityBio's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
ImmunityBio Inc is a late-clinical-stage immunotherapy company developing next-generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. Geographically, the company operates in United States and Europe. Majority of the revenue is generated from Europe.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
IBRX has been successfully added to your 